Screening for liver metastases in high-risk colorectal cancer patients using MRI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of Diffusion Weighted MRI (DW-MRI) in detecting synchronous liver metastases in patients with high-risk colorectal cancer, compared to standard CT imaging. Eligible participants will undergo DW-MRI scans every six months for three years following surgery, provided they have no prior evidence of liver metastases. The findings from these scans will be shared with local multidisciplinary teams (MDTs) to guide treatment decisions for any identified liver metastases. The goal is to improve early detection and management of metastatic disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Have a high risk primary colorectal malignancy
2. Have a negative CT or includes no confirmatory evidence of liver metastases
3. Is able to undergo treatment if liver metastasis is found
4. Have provided written informed consent to participate in the study
5. Be aged 16 years or over

Exclusion Criteria:

1. Have had a previous colorectal malignancy
2. Have metastatic disease
3. Have a synchronous second malignancy
4. Are contraindicated for MRI
5. Has a T3b or below low rectal tumour without EMVI or N1c

Where it's running

• Macclesfield District General Hospital
  Macclesfield, Cheshire, United Kingdom Recruiting
• Broomfield Hospital
  Chelmsford, Essex, United Kingdom Recruiting
• Royal Bolton Hospital
  Bolton, Greater Manchester, United Kingdom Recruiting
• Medway Maritime Hospital
  Gillingham, Kent, United Kingdom Recruiting
• University Hospital of South Manchester & Manchester Royal Infirmary
  Wythenshawe, Manchester, United Kingdom Recruiting
• Royal Liverpool Hospital
  Liverpool, Merseyside, United Kingdom Recruiting

Study contacts

• Principal investigator: Gina Brown — Imperial College London
• Study coordinator: Caroline Martin
• Email: c.martin1@imperial.ac.uk
• Phone: +44 (0) 7749 655 817

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples

  This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.

  Recruiting at 2 sites Vorarlberg Institute for Vascular Investigation and Treatment · Bregenz, Vorarlberg and 3 other locations · NCT07913802

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer

  A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.

  Recruiting Masaryk Memorial Cancer Institute · Brno, Czech Republic · NCT07895459

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery

  Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07830576

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.